Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis

Morie Gertz, Martha Lacy, Angela Dispenzieri, Suzanne Hayman, Shaji Kumar, Francis Buadi, Nelson Leung, Mark Litzow

Research output: Contribution to journalArticle

69 Scopus citations

Abstract

The efficacy of stem cell transplantation in amyloidosis largely is determined by treatment-related mortality rates (range, 11-25%). Appropriate patient selection is essential to avoid this high mortality rate. Among 271 patients undergoing stem cell transplantation, troponin T was a powerful predictor of treatment-related mortality. Patients with troponin T levels of 0.06μg/L or higher had a day-100 all-cause mortality rate of 28%. Patients with troponin T levels less than 0.06μg/L had a day-100 all-cause mortality rate of 7% (P<0.001). Troponin T levels should be measured in all patients before transplantation. Those with troponin T levels exceeding 0.06μg/L should be considered for less toxic therapies until the clinically optimal use of stem cell transplantation is better defined by randomized clinical trials.

Original languageEnglish (US)
Pages (from-to)36-41
Number of pages6
JournalLeukemia and Lymphoma
Volume49
Issue number1
DOIs
StatePublished - Jan 1 2008

Keywords

  • Amyloidosis
  • Multiple myeloma
  • Restrictive cardiomyopathy
  • Stem cell transplantation
  • Troponin T

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis'. Together they form a unique fingerprint.

  • Cite this